Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing the market potential of TYMLOS (Abaloparatide) after approval and positive ACTIVExtend results in osteoporosis.

Ticker(s): RDUS, MRK, AMGN, LLY

Who's the expert?

Name: Dr Tamara Vokes - MD

Institution:  University of Chicago

  • Professor in the Section of Endocrinology at the University of Chicago.
  • Treats ~500 patients with osteoporosis and is in the process of prescribing TYMLOS.
  • Clinical and research activities center around osteoporosis and metabolic bone disease, and she has significant publications in these areas..

Interview Questions
Q1.

Please describe your clinical practice and how many postmenopausal women you treat with osteoporosis at high risk for fracture.

Added By: joe_mccann
Q2.

Which of your patients are you most likely to have try TYMLOS?

Added By: joe_mccann
Q3.

How do you view the side effect profile of TYMLOS? Does the black box warning on osteosarcoma concern you?

Added By: joe_mccann
Q4.

Please explain the mode of action and can you compare the benefit vs other products including
1. Decrease in fracture risk at the femoral neck and lumbar spine
2. Increase in BMD vs competitors 

Added By: joe_mccann
Q5.

FORTEO and abaloparatide-SC are daily injections, whereas romosozumab is injected once a month. How will this affect the popularity of each drug?  Do these differences suggest romosozumab fits a niche market within osteoporosis?

Added By: joe_mccann
Q6.

How does the side effect profile of TYMLOS compare to Forteo and Prolia in your opinion?

Added By: joe_mccann

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.